DK2970383T3 - Fremgangsmåde til behandling af fibrose - Google Patents

Fremgangsmåde til behandling af fibrose Download PDF

Info

Publication number
DK2970383T3
DK2970383T3 DK14762435.7T DK14762435T DK2970383T3 DK 2970383 T3 DK2970383 T3 DK 2970383T3 DK 14762435 T DK14762435 T DK 14762435T DK 2970383 T3 DK2970383 T3 DK 2970383T3
Authority
DK
Denmark
Prior art keywords
treating fibrosis
fibrosis
treating
Prior art date
Application number
DK14762435.7T
Other languages
Danish (da)
English (en)
Inventor
Sreerama Shetty
Steven Idell
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of DK2970383T3 publication Critical patent/DK2970383T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK14762435.7T 2013-03-15 2014-03-17 Fremgangsmåde til behandling af fibrose DK2970383T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361800117P 2013-03-15 2013-03-15
PCT/US2014/030147 WO2014145389A1 (en) 2013-03-15 2014-03-17 Inhibition of pulmonary fibrosis with nutlin-3a and peptides

Publications (1)

Publication Number Publication Date
DK2970383T3 true DK2970383T3 (da) 2021-07-05

Family

ID=51537978

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14762435.7T DK2970383T3 (da) 2013-03-15 2014-03-17 Fremgangsmåde til behandling af fibrose
DK21168926.0T DK3929207T3 (da) 2013-03-15 2014-03-17 Peptid fttftvt til anvendelse i behandling af fibrose

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21168926.0T DK3929207T3 (da) 2013-03-15 2014-03-17 Peptid fttftvt til anvendelse i behandling af fibrose

Country Status (11)

Country Link
US (8) US9630990B2 (enExample)
EP (3) EP4438044A3 (enExample)
JP (4) JP6603207B2 (enExample)
KR (3) KR102268883B1 (enExample)
CN (3) CN105263948B (enExample)
AU (3) AU2014233055B2 (enExample)
CA (1) CA2904870C (enExample)
DK (2) DK2970383T3 (enExample)
ES (2) ES2875853T3 (enExample)
PT (2) PT2970383T (enExample)
WO (1) WO2014145389A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
EP3061808B1 (en) 2009-02-03 2020-08-12 Koninklijke Nederlandse Akademie van Wetenschappen Culture medium for epithelial stem cells and organoids comprising said stem cells
KR102268883B1 (ko) * 2013-03-15 2021-06-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
CA2939121C (en) 2014-01-28 2020-11-24 Mayo Foundation For Medical Education And Research Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
AU2015261380B2 (en) 2014-05-16 2021-04-15 Koninklijke Nederlandse Akademie Van Wetenschappen Improved culture method for organoids
GB201421092D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
GB201421094D0 (en) 2014-11-27 2015-01-14 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium
EP3261657A1 (en) * 2015-02-27 2018-01-03 Board of Regents, The University of Texas System Polypeptide therapeutics and uses thereof
GB201603569D0 (en) 2016-03-01 2016-04-13 Koninklijke Nederlandse Akademie Van Wetenschappen Improved differentiation method
WO2018190680A1 (ko) * 2017-04-13 2018-10-18 충남대학교산학협력단 세포내 결핵균 제어를 위한 뉴트린-3α 및 피53 발현 조절 조성물 또는 방법
KR102082285B1 (ko) * 2017-04-13 2020-02-28 충남대학교산학협력단 세포내 결핵균 제어를 위한 Nutlin-3α (뉴트린-3α) 및 p53 발현 조절 조성물 또는 방법
CN107987128B (zh) * 2017-11-17 2019-06-11 广东医科大学 一种功能多肽及其在制备防治肺纤维化药物中的应用
US12281180B2 (en) 2018-07-13 2025-04-22 New York University Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
WO2020055824A1 (en) * 2018-09-10 2020-03-19 Board of Regents, The University of the Texas System Dry powder formulation of caveolin-1 peptides and methods of use thereof
WO2020055812A1 (en) 2018-09-10 2020-03-19 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis
CN109010798A (zh) * 2018-09-17 2018-12-18 中山大学中山眼科中心 一种多肽的新用途
GB201819224D0 (en) 2018-11-26 2019-01-09 Koninklijke Nederlandse Akademie Van Wetenschappen Hepatocyte expansion methods
JP7640976B2 (ja) * 2019-12-31 2025-03-06 シァメン・ユニヴァーシティ 分子の細胞内送達用の多量体化送達システム
EP4297768A4 (en) 2021-02-25 2025-01-15 Lung Therapeutics, LLC Biomarkers for the treatment of interstitial lung disease
WO2022217037A1 (en) * 2021-04-09 2022-10-13 Board Of Regents, The University Of Texas System Compositions and methods for treatment of chronic lung diseases
WO2025007890A1 (zh) * 2023-07-06 2025-01-09 厦门大学 新型疫苗递送体系
CN116789751B (zh) * 2023-08-22 2023-11-17 中国农业大学 预防和/或治疗纤维化疾病的多肽及其应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4021387A (en) 1975-11-19 1977-05-03 President And Fellows Of Harvard College Eosinophilotactic tetrapeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4816449A (en) 1984-08-09 1989-03-28 Immunetech Pharmaceuticals Immunotherapeutic anti-inflammatory peptide agents
US4613676A (en) * 1983-11-23 1986-09-23 Ciba-Geigy Corporation Substituted 5-amino-4-hydroxyvaleryl derivatives
ZA846192B (en) 1984-08-09 1986-03-26 Merck Patent Gmbh Immunotherapeutic polypeptide agents
US5728680A (en) 1987-12-30 1998-03-17 Cytoven J.V. Methods for normalizing numbers of lymphocytes
DK53291D0 (da) * 1991-03-25 1991-03-25 Carlbiotech Ltd As Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser
CA2150371C (en) * 1992-12-11 2002-09-17 Dov Borovsky Materials and methods for control of pests
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US6017735A (en) 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
US20030113271A1 (en) 1997-01-29 2003-06-19 University Technology Corporation Formulations for pulmonary delivery
EP1076091A1 (en) 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
US20020077283A1 (en) 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
EP1353676A4 (en) 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
GB0119852D0 (en) 2001-08-15 2001-10-10 Univ York Baculovirus
WO2003051359A1 (en) 2001-12-18 2003-06-26 F.Hoffmann-La Roche Ag Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
WO2005092301A1 (en) 2004-03-26 2005-10-06 Universita' Degli Studi Di Parma Insulin highly respirable microparticles
KR20070047246A (ko) * 2004-05-25 2007-05-04 아테뉴온, 엘엘씨 유로키나아제형 플라스미노겐 활성인자(ｕＰＡ)와 그의수용체(ｕＰＡＲ)의 복합체에 결합하여 하류 ｕＰＡＲ상호작용을 억제하는 리간드의 동정 및 진단 또는치료에서의 용도
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
TWI299993B (en) 2005-12-15 2008-08-21 Dev Center Biotechnology Aqueous inhalation pharmaceutical composition
US8058227B2 (en) * 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
WO2008046228A1 (en) 2006-10-19 2008-04-24 Angiochem, Inc. Compounds for stimulating p-glycoprotein function and uses thereof
CA2707986A1 (en) 2007-12-13 2009-06-18 Glaxo Group Limited Compositions for pulmonary delivery
KR101593708B1 (ko) * 2007-12-21 2016-02-12 피브로테크 세라퓨틱 피티와이 엘티디 항섬유증 제제의 할로겐화 유사체
WO2009111625A2 (en) * 2008-03-05 2009-09-11 Board Of Regents, The University Of Texas System Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
KR20110051245A (ko) 2008-09-10 2011-05-17 제넨테크, 인크. 안구 혈관신생의 억제 방법
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
HUE044292T2 (hu) 2010-02-11 2019-10-28 Ablynx Nv Eljárások és készítmények aeroszolok elõállítására
EP2635686B1 (en) 2010-11-05 2018-03-28 The Regents of The University of California Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
WO2013184482A1 (en) * 2012-06-04 2013-12-12 Yale University Method of treating and preventing ocular angiogenesis
US10441536B2 (en) 2013-03-13 2019-10-15 Actavis Group Ptc Ehf Micronized colistimethane sodium pharmaceutical compositions
KR102268883B1 (ko) 2013-03-15 2021-06-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 누트린-3a 및 펩티드에 의한 폐 섬유증의 저해
WO2015066664A2 (en) 2013-11-04 2015-05-07 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
US9908915B2 (en) 2013-11-26 2018-03-06 Yale University Cell-penetrating compositions and methods using same
WO2015080980A2 (en) 2013-11-26 2015-06-04 E&B Technologies Llc Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators
WO2020055824A1 (en) 2018-09-10 2020-03-19 Board of Regents, The University of the Texas System Dry powder formulation of caveolin-1 peptides and methods of use thereof
WO2020055812A1 (en) 2018-09-10 2020-03-19 Lung Therapeutics, Inc. Modified peptide fragments of cav-1 protein and the use thereof in the treatment of fibrosis

Also Published As

Publication number Publication date
US11161875B2 (en) 2021-11-02
US20240059736A1 (en) 2024-02-22
US20250304619A1 (en) 2025-10-02
CN117679487A (zh) 2024-03-12
EP2970383A1 (en) 2016-01-20
AU2018205157A1 (en) 2018-08-02
JP2021178856A (ja) 2021-11-18
KR20150128731A (ko) 2015-11-18
ES2993671T3 (en) 2025-01-03
EP4438044A2 (en) 2024-10-02
JP2018158952A (ja) 2018-10-11
US20180086791A1 (en) 2018-03-29
KR102268883B1 (ko) 2021-06-28
PT3929207T (pt) 2024-10-21
US11780879B2 (en) 2023-10-10
PT2970383T (pt) 2021-06-03
EP4438044A3 (en) 2024-12-04
KR20230148263A (ko) 2023-10-24
US10377796B2 (en) 2019-08-13
US9630990B2 (en) 2017-04-25
HK1218924A1 (zh) 2017-03-17
US20200165298A1 (en) 2020-05-28
DK3929207T3 (da) 2024-10-21
CN105263948A (zh) 2016-01-20
JP6975690B2 (ja) 2021-12-01
JP2023178440A (ja) 2023-12-14
CA2904870C (en) 2022-08-23
AU2020203192A1 (en) 2020-06-04
EP2970383B1 (en) 2021-04-21
AU2014233055A1 (en) 2015-10-01
JP6603207B2 (ja) 2019-11-06
US20220098239A1 (en) 2022-03-31
EP2970383A4 (en) 2016-12-21
WO2014145389A1 (en) 2014-09-18
BR112015023287A2 (pt) 2019-11-19
CN110201144A (zh) 2019-09-06
US12173089B2 (en) 2024-12-24
US20230100467A1 (en) 2023-03-30
JP7378833B2 (ja) 2023-11-14
US20160272678A1 (en) 2016-09-22
EP3929207A1 (en) 2021-12-29
CN110201144B (zh) 2024-01-02
EP3929207B1 (en) 2024-07-17
KR102588702B1 (ko) 2023-10-16
US20170253632A1 (en) 2017-09-07
KR20210076190A (ko) 2021-06-23
ES2875853T3 (es) 2021-11-11
AU2014233055B2 (en) 2018-08-09
CN105263948B (zh) 2019-06-04
CA2904870A1 (en) 2014-09-18
JP2016522159A (ja) 2016-07-28

Similar Documents

Publication Publication Date Title
DK2970383T3 (da) Fremgangsmåde til behandling af fibrose
IL246002A0 (en) Novel methods
IL249981A0 (en) Method
LT2964417T (lt) Būdas kiaurinėms angoms pagrinde įvesti
DK3110988T3 (da) Metoder til behandling af lithiumholdige materialer
LT3074534T (lt) Būdai, skirti polinukleotido sekoskaitai
DK3316703T3 (da) Fremgangsmåde til forbedring af dyrs ydeevne
EP2992997A4 (en) METHOD OF ABROADING
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3013544T3 (da) Fremgangsmåde til betonfremstilling
EP2937552A4 (en) ROCKET MOTOR, ROCKET AND METHOD FOR STARTING A ROCKET MOTOR
DK2857019T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK2956071T3 (da) Sæt til perifer nerveblokering
DK3044788T3 (da) Ikke-uniform parameterkvantificering til avanceret kobling
BR112015029436A2 (pt) método de modificação de polímeros
BR112015021083A2 (pt) método
FR3001642B1 (fr) Procede de recouvrement de surfaces
BR112015029076A2 (pt) método
DK3016682T3 (da) Metoder til behandling af kræft
FI20135361L (fi) Analyyttinen menetelmä
DK2837678T3 (da) Fremgangsmåde til forbedret afsmeltning
FI20135226L (fi) Prosessi bioöljyn modifioimiseksi
DK2986325T3 (da) Fremgangsmåder til behandling af forstyrrelser i urinstofcyklus
DK3047025T3 (da) Fremgangsmåde til fremstilling af kappevira
DK3042205T3 (da) Fremgangsmåde til forbedring af antistofstabilitet